Compare AbbVie Inc (ABBV) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Petróleo Brasileiro SA — how do they compare? AbbVie Inc trades at $248.68 (market cap $438.19B), while Petróleo Brasileiro SA trades at $18.01 (market cap $114.31B). The key difference: AbbVie Inc is far larger — about 3.8× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.62%). Which is the better fit depends on your goals.
| ABBV | PBR | |
|---|---|---|
Market Cap | $438.19B | $114.31B |
Sector | Health | Technology |
52-Week High | $263.58 | $22.03 |
52-Week Low | $197.38 | $11.54 |
Enterprise Value | $502.45B | $174.73B |
Dividend Yield | 2.79% | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
PBR trades at $17.96, down 3.02% today, with bearish technical signals but strong fundamentals. The company reported robust Q2 2026 results with record production of 3.34 million boe/day and net earnings surging 120% year-over-year. Valuation metrics remain attractive with P/E of 4.63 and ROE of 30.77%. Analyst consensus is bullish with 11 buy ratings out of 22 total coverage.
PBR presents a compelling value opportunity with strong profitability and dividend yield, though regulatory uncertainty and oil price volatility pose risks. The company's production growth trajectory and cost-efficient pre-salt assets support long-term upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
